RT Journal Article
T1 Drug Repurposing for Triple-Negative Breast Cancer.
A1 Ávalos-Moreno, Marta
A1 López-Tejada, Araceli
A1 Blaya-Cánovas, Jose L
A1 Cara-Lupiañez, Francisca E
A1 González-González, Adrián
A1 Lorente, Jose A
A1 Sánchez-Rovira, Pedro
A1 Granados-Principal, Sergio
K1 cancer stem cells
K1 clinical trials
K1 computational methods
K1 drug repurposing
K1 personalized medicine
K1 triple-negative breast cancer
AB Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer which presents a high rate of relapse, metastasis, and mortality. Nowadays, the absence of approved specific targeted therapies to eradicate TNBC remains one of the main challenges in clinical practice. Drug discovery is a long and costly process that can be dramatically improved by drug repurposing, which identifies new uses for existing drugs, both approved and investigational. Drug repositioning benefits from improvements in computational methods related to chemoinformatics, genomics, and systems biology. To the best of our knowledge, we propose a novel and inclusive classification of those approaches whereby drug repurposing can be achieved in silico: structure-based, transcriptional signatures-based, biological networks-based, and data-mining-based drug repositioning. This review specially emphasizes the most relevant research, both at preclinical and clinical settings, aimed at repurposing pre-existing drugs to treat TNBC on the basis of molecular mechanisms and signaling pathways such as androgen receptor, adrenergic receptor, STAT3, nitric oxide synthase, or AXL. Finally, because of the ability and relevance of cancer stem cells (CSCs) to drive tumor aggressiveness and poor clinical outcome, we also focus on those molecules repurposed to specifically target this cell population to tackle recurrence and metastases associated with the progression of TNBC.
SN 2075-4426
YR 2020
FD 2020-10-29
LK https://hdl.handle.net/10668/24547
UL https://hdl.handle.net/10668/24547
LA en
DS RISalud
RD Apr 4, 2025